TDC
NVAX icon

Thompson Davis & Co’s Novavax NVAX Stock Holding History

Thompson Davis & Co’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-375
Closed -$9K – 1166
2017
Q2 		$9K Sell
375
-375
-50% -$7.36K 0.01% 691
2017
Q1 		$19K Buy
+750
New +$20.6K 0.03% 515
2015
Q4 		– Sell
-25
Closed -$4K – 1173
2015
Q3 		$4K Sell
25
-38
-60% -$8.52K 0.01% 890
2015
Q2 		$14K Buy
63
+13
+26% +$2.29K 0.02% 646
2015
Q1 		$8K Buy
+50
New +$8.12K 0.01% 794

Other funds holding NVAX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Thompson Davis & Co's NVAX Position: Q3 2017 in Review

Thompson Davis & Co sold out of Novavax (NVAX) in Q3 2017, closing a stake of 375 shares — an estimated $9K sold.

Thompson Davis & Co first reported a position in NVAX in Q1 2015 and held it in 5 quarters. The position peaked at $19K in Q1 2017. 128 funds tracked by Wall St. Rank hold NVAX as of Q3 2017.

  • Thompson Davis & Co reported no remaining Novavax position as of Q3 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 375 Novavax shares in Q3 2017, an estimated $9K.
  • Thompson Davis & Co first reported a position in Novavax in Q1 2015 and held it in 5 quarters.
  • Thompson Davis & Co's Novavax position peaked at $19K in Q1 2017.
  • 128 funds tracked by Wall St. Rank held Novavax as of Q3 2017.

Based on Thompson Davis & Co's 13F filing for Q3 2017, filed 30 Oct 2017.